HR091506 / Jiangsu Hengrui Pharma - LARVOL DELTA

Efficacy and Safety of HR091506 Extended-Release Tablets Versus Febuxostat in Patients With Gout and Hyperuricemia: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase 3 Trial (ACR Convergence 2026) - P3 | "HR091506 40 mg demonstrated superior serum uric acid-lowering efficacy versus febuxostat in patients with gout and hyperuricemia and was well tolerated, with a favorable safety profile."

Clinical • P3 data • Gout • Inflammatory Arthritis • Rheumatology

Efficacy and safety of HR091506 extended-release tablets in patients with gout, hyperuricemia, and recurrent flares, tophi, or chronic gouty arthropathy: a multicenter, randomized, double-blind phase 3 trial (EULAR 2026) - P3 | "Background Febuxostat immediate release, a xanthine oxidase inhibitor, is used to manage hyperuricemia in gout by reducing urate levels. (optional) Image 2. (optional)"

Clinical • Late-breaking abstract • P3 data • Gout • Inflammatory Arthritis • Rheumatology

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (clinicaltrials.gov) - P3 | N=765 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Completed | N=18 ➔ 36

Enrollment change • Trial completion

A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial

Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (clinicaltrials.gov) - P3 | N=434 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P3 trial • Gout • Inflammatory Arthritis • Rheumatology

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (clinicaltrials.gov) - P3 | N=750 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Trial completion date • Trial initiation date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (clinicaltrials.gov) - P3 | N=750 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P3 trial • Gout • Inflammatory Arthritis • Rheumatology

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology